89bio reaches alignment with the fda and ema on phase 3 program for pegozafermin in nonalcoholic steatohepatitis (nash); program initiation planned in the first half of 2024

—alignment reached on key elements of the nash development strategy, including accelerated approval pathway for both f4 and f2-f3 nash patients using histology—

ETNB Ratings Summary

ETNB Quant Ranking